Western Companies Moderna announced topline results from a Phase 3 pivotal trial evaluating mRNA-1647, an investigational cytomegalovirus (CMV) vaccine. The study did not meet its primary efficacy endpoint of preventing CMV infection in seronegative female participants of childbearing age (16–40 years). Pfizer and BioNTech reported positive topline data for their new LP.8.1-adapted COVID-19 vaccine (2025–2026 formula), demonstrating at least a 4-fold increase in neutralizing antibody titers against the LP.8.1 sublineage in high-risk adult cohorts. These results support prior preclinical findings and have been submitted to regulatory authorities following recent FDA approval. Novavax signed new $60 million agreements to streamline its US portfolio after updated COVID-19 vaccination guidance impacted market access. Asian Companies Asia-Pacific remains a global powerhouse for vaccine clinical trials, with recruitment rates nearly four times faster than North America – according to Pharma Focus Asia. China remains the leader in mRNA and viral vector platforms, with Sinovac and CanSino Biologics prominent in respiratory...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!
